The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Inflammation in obesity, diabetes, and related disorders
Immunity. 2022 Jan 11;55(1):31-55. doi: 10.1016/j.immuni.2021.12.013.
1Division of Endocrinology and Metabolism, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
2Clinic of Endocrinology, Diabetes and Metabolism, University Hospital Basel, Basel 4031, Switzerland; Department of Biomedicine (DBM), University of Basel, University Hospital Basel, Basel 4031, Switzerland.
3Clinic of Endocrinology, Diabetes and Metabolism, University Hospital Basel, Basel 4031, Switzerland; Department of Biomedicine (DBM), University of Basel, University Hospital Basel, Basel 4031, Switzerland. Electronic address: marc.donath@usb.ch.
Abstract
Obesity leads to chronic, systemic inflammation and can lead to insulin resistance (IR), β-cell dysfunction, and ultimately type 2 diabetes (T2D). This chronic inflammatory state contributes to long-term complications of diabetes, including non-alcoholic fatty liver disease (NAFLD), retinopathy, cardiovascular disease, and nephropathy, and may underlie the association of type 2 diabetes with other conditions such as Alzheimer's disease, polycystic ovarian syndrome, gout, and rheumatoid arthritis. Here, we review the current understanding of the mechanisms underlying inflammation in obesity, T2D, and related disorders. We discuss how chronic tissue inflammation results in IR, impaired insulin secretion, glucose intolerance, and T2D and review the effect of inflammation on diabetic complications and on the relationship between T2D and other pathologies. In this context, we discuss current therapeutic options for the treatment of metabolic disease, advances in the clinic and the potential of immune-modulatory approaches.